@misc{10481/103047,
year = {2024},
month = {5},
url = {https://hdl.handle.net/10481/103047},
abstract = {The lack of specific symptoms in patients and the absence of a reliable and well-stablished diagnostic method,
makes advanced pancreatic ductal adenocarcinoma (PDAC) the most common clinical appearance of pancreatic cancer
cases. In these circumstances, surgical resection, the only curative approach for this malignancy, is unaffordable, leading to
very low survival outcomes. Immunotherapy is a recent approach that has been studied in many cancer types showing
encouraging results, but it has not been sufficiently investigated in PDAC. We report the case of a patient with unresectable
PDAC that progressed to metastasis after treatment with chemoradiation, who showed an outstanding response to immuno-
therapy with pembrolizumab, achieving a complete remission within a few months, which was maintained until the end of
treatment. Currently, the patient continues in disease-free state.},
organization = {Spanish Ministry of Universities María Zambrano postdoctoral fellowship},
organization = {Next Generation European Union},
publisher = {Baishideng Publishing Group Inc.},
keywords = {Pancreatic ductal adenocarcinoma},
keywords = {Lung cancer;},
keywords = {Immunotherapy},
keywords = {Pembrolizumab},
keywords = {Programmed cell death protein- 1},
keywords = {Case report},
title = {Metastatic pancreatic and lung cancer patient in complete remission following immunotherapy: A case report and review of literature},
doi = {10.4251/wjgo.v16.i5.2233},
author = {Martínez Galán, Joaquina and Jiménez Luna, Cristina and Rodríguez, Isabel and Maza, Elisabeth and García Collado, Carlos and Rodríguez Fernández, Antonio and López Hidalgo, Javier Luis and Caba Pérez, Octavio},
}